Phaseline

Companies › GenomeFrontier Therapeutics TW

GenomeFrontier Therapeutics TW: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GF-CART01
CD20/CD19-targeting CAR T cell therapy
CD20, CD19Phase 1Diffuse Large B Cell Lymphoma RelapsedMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06703892GF-CART01Phase 1Diffuse Large B Cell Lymphoma RelapsedOncologyMar 2027

Targets

CD20 (1) CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Roche Allogene Therapeutics Miltenyi Biomedicine Lyell Immunopharma AvenCell Therapeutics Shanghai AbelZeta

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.